SLO-POT TABLET (EXTENDED-RELEASE)

Country: Canada

Language: English

Source: Health Canada

Active ingredient:

POTASSIUM CHLORIDE

Available from:

BIOMED PHARMA

ATC code:

A12BA01

INN (International Name):

POTASSIUM CHLORIDE

Dosage:

600MG

Pharmaceutical form:

TABLET (EXTENDED-RELEASE)

Composition:

POTASSIUM CHLORIDE 600MG

Administration route:

ORAL

Units in package:

100/1000

Prescription type:

Ethical

Therapeutic area:

REPLACEMENT PREPARATIONS

Product summary:

Active ingredient group (AIG) number: 0100273010; AHFS:

Authorization status:

APPROVED

Authorization date:

2005-06-01

Summary of Product characteristics

_Slo-Pot Product Monograph _
_Page 1 of 8 _
1
PRODUCT MONOGRAPH
SLO-POT
SLOW-RELEASE POTASSIUM CHLORIDE TABLETS
(600 MG)
POTASSIUM SUPPLEMENT
BIOMED 2002 INC.
DATE OF PREPARATION: SEPTEMBER 30, 2014
5950, Côte de Liesse, Suite100
Ville Mont-Royal
Québec H4T 1E2
Control # 177869
_Slo-Pot Product Monograph _
_Page 2 of 8 _
2
PRODUCT MONOGRAPH
SLO-POT
SLOW-RELEASE POTASSIUM CHLORIDE TABLETS
(600 MG)
POTASSIUM SUPPLEMENT
ACTION:
Potassium
ions
participate
in
numerous
essential
physiological
processes
including
the
maintenance of intracellular tonicity, the transmission of nerve
impulses, the contraction of
cardiac,
skeletal,
smooth
muscle
and
the
maintenance
of
normal
renal
function.
(See
PHARMACOLOGY). Depletion may occur whenever the rate of potassium loss
through renal
excretion and/or loss from the gastrointestinal tract exceeds the rate
of potassium intake. SLO-
POT provides a controlled release, over a period of 4-5 hours, of
potassium chloride from a
wax matrix, thereby minimizing the possibility of producing high
localized concentration of
potassium within the gastrointestinal tract.
INDICATIONS:
SLO-POT
(potassium
chloride)
is
indicated
for
the
treatment
of
potassium
depletion
in
patients
with
hypokalemia
and
metabolic
alkalosis
and
for
the
treatment
of
digitalis
intoxication.
SLO-POT is also indicated for the prevention of potassium depletion
when the dietary intake
of potassium is inadequate for this purpose.
The prophylactic administration of potassium ion may be indicated in
patients receiving
digitalis and diuretics for the treatment of congestive heart failure
and hepatic cirrhosis with
ascites. SLO-POT may be indicated in selected hypertensive patients on
long-term diuretic
therapy, hyperaldosteronism states with normal renal function, the
nephrotic syndrome and
certain diarrheal states.
CONTRAINDICATIONS:
SLO-POT
(potassium
chloride)
is
contraindicated
in
renal
impairment
with
oliguria
or
azotemia,
untreated
Addison's
disease,
hyperadrenalism
associated
with
adrenogenital
syndrome, extensive tissue